No Data
Carna Biosciences: Interim report.
The market is soft, and with pressures like the decline in U.S. stocks, but the downside may be limited.
[Emerging Markets Individual Stocks Global Strategy] Today's Emerging Markets are expected to show a sluggish development. In the US stock market on the 27th, the Dow Inc. fell by 155.09 points (-0.37%) to 42,299.70 dollars, continuing its decline. Concerns over the automobile tariffs announced by President Trump, along with speculation of persistent high inflation, led to a dislike of rising long-term interest rates. On the other hand, indicators such as employment-related data and gross domestic product (GDP) pointed to a robust economy, causing the Dow Inc. to briefly turn upward, but uncertainty regarding tariffs lingered towards the end.
Carna Biosciences: Confirmation
Carna Biosciences: Securities Report - 22nd Term (2024/01/01 - 2024/12/31)
The market is stable, supported by the rise in U.S. stocks, but resistance may be strong at higher levels.
[Emerging Markets Individual Stock Strategy] Today's Emerging Markets are expected to show a solid performance. On the US Stock Market yesterday, October 24, the Dow Inc rose significantly by 597.97 points (+1.42%) to 42,583.32 dollars. Reports suggested that the Trump administration's 'reciprocal tariffs' would be focused, and the unexpected rise in the March Services PMI supported stock prices. The buybacks in the high-tech sector continued, expanding the gain into the latter part of the day. Today's Emerging Markets are likely to experience a favorable buying trend.
Carnavbio continues to rise, extending the contract for joint research and commercialization with Sumitomo Pharma.
Carnabio <4572.T> continues to rise, reaching a temporary high of 6 yen at 292 yen. After the market close on the 19th, it was announced that they extended a joint research agreement with Sumitomo Pharma <4506.T>, as well as subsequent development and commercialization, which was viewed as significant news. The company entered into a joint research agreement in March 2018 aimed at creating new kinase inhibitors targeting mental and neurological disorders, and new candidate compounds for drugs in the mental and neurological disorder domain have been discovered in the joint research.